• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Do Vitamin D3 Supplements Reduce Mortality Among Older Adults?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Previous randomized controlled trials have investigated the impact of vitamin D3 supplementation on a variety of health outcomes, but so far none have examined all-cause mortality as the primary outcome
  • Neale et al. (Lancet Diabetes and Endocrinology, 2022) sought to determine whether monthly doses of vitamin D3 influenced mortality in older adults

METHODS:

  • Randomized, double-blind, placebo-controlled trial
    • Australian population
  • Participants
    • Adults ≥60 years 
  • Interventions
    • Vitamin D3 supplementation: 60,000 IU gel cap monthly for 5 years
    • Placebo
  • Study design
    • Randomized 1:1
    • Hazard ratios (HRs) and 95% CIs were generated
  • Primary outcome
    • All-cause mortality
  • Secondary outcomes
    • Mortality from cancer
    • Mortality from cardiovascular disease
    • Mortality from other causes

RESULTS:

  • Vitamin D group: 10,662 participants | Placebo: 10,653 participants
    • Median follow-up: 5.7 years (IQR 5.4 to 6.7)
  • Mean serum 25-hydroxy-vitamin D concentrations (in blood samples collected from randomly sampled participants)
    • Vitamin D group: 115 (SD 30) nmol/L
    • Placebo group: 77 (SD 25) nmol/L
  • Mortality after 5 years of intervention
    • Vitamin D: 5.3% of group
    • Placebo: 5.1% of group
  • There was no significant effect of vitamin D3 on
    • All-cause mortality
      • HR 1.04 (95% CI, 0.93 to 1.18); P=0.47
    • Cardiovascular disease mortality
      • HR 0.96 (95% CI, 0.72 to 1.28); P=0.77
    • Cancer mortality
      • HR 1.15 (95% CI, 0.96 to 1.39); P=0.13
    • Mortality from other causes
      • HR 0.83 (95% CI, 0.65 to 1.07); P=0.15
  • In exploratory analyses excluding the first 2 years of follow-up, those in the vitamin D group had a higher hazard of cancer mortality than those in the placebo group
    • HR 1.24 (95% CI, 1.01 to 1.54); P=0.05

CONCLUSION:

  • Vitamin D3 supplementation in a population of unscreened older adults did not significantly reduce all-cause mortality, or mortality due to other causes
  • The authors state

Point estimates and exploratory analyses excluding the early follow-up period were consistent with an increased risk of death from cancer

Pending further evidence, the precautionary principle would suggest that this dosing regimen might not be appropriate in people who are vitamin D-replete

Learn More – Primary Sources:

The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Vitamin D Supplementation Decrease Mortality Risk?
Do Vitamin D and Calcium Supplements Decrease Cancer Risk?
Do High Dose Vitamin D Supplements During the Third Trimester Improve Offspring Neurodevelopmental Outcomes?
Is there a Causal Link between Vitamin D and Gestational Hypertension / Preeclampsia?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site